According to filings with the U.S. Securities and Exchange Commission, Aakha Biologics is raising up to $5,000,000.00 in new funding. Sources indicate that as part of senior management President, Hemanta Baruah played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aakha Biologics
Aakha Biologics is a new kind of biotech company that values efficiency in the drug discovery process to more rapidly bring high quality therapeutics to patients. Aakha is developing biologics that boost the bodys immuno surveillance against tumors and is harnessing multiple advanced antibody discovery platforms to empower its scientists to advance drug candidates from concept to IND-enabling studies. It is led by founder and CEO Hemanta Baruah, a proven drug discoverer with an approved biologic and several additional candidates currently in clinical trials. Aakha was created through a collaborative partnership model with Alloy Therapeutics affiliated venture studio 82VS, which leverages access to Alloys ATX-Gx transgenic mouse, suite of antibody discovery platforms, and discovery services.

To learn more about Aakha Biologics, visit http://aakha.bio/
Aakha Biologics Linkedin Page: https://www.linkedin.com/company/aakha-biologics/

Contact:
Hemanta Baruah, President
617-276-4715

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.